K.J. Harrison & Partners Inc Purchases New Holdings in Illumina, Inc. $ILMN

Key Points

• K.J. Harrison & Partners acquired 10,000 Illumina shares worth approximately $1.76 million in the second quarter. Institutional investors and hedge funds collectively own 89.42% of the company.
• Illumina beat quarterly expectations, reporting $1.31 in EPS and $1.16 billion in revenue, with revenue up 9.4% year over year. The company issued fiscal 2026 EPS guidance of $5.30–$5.40.
• Analysts raised several price targets, including RBC’s increase to $230 and Piper Sandler’s to $225, but the overall consensus remains “Hold” with a $188.40 price target. Insiders sold more than 1.4 million shares worth approximately $256 million over the past three months.

K.J. Harrison & Partners Inc acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 10,000 shares of the life sciences company's stock, valued at approximately $1,758,000.

A number of other hedge funds have also made changes to their positions in ILMN. BlackRock Inc. purchased a new stake in Illumina during the 2nd quarter valued at about $3,374,423,000. Pallas Capital Advisors LLC purchased a new position in Illumina in the 2nd quarter worth approximately $4,486,000. Deutsche Bank AG acquired a new position in shares of Illumina during the 2nd quarter worth approximately $68,999,000. Perigon Wealth Management LLC acquired a new position in shares of Illumina during the 2nd quarter worth approximately $1,004,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Illumina in the second quarter valued at approximately $30,501,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Performance

Shares of Illumina stock opened at $193.13 on Tuesday. The firm has a market cap of $29.16 billion, a PE ratio of 36.03, a price-to-earnings-growth ratio of 2.69 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $207.00. The business's fifty day simple moving average is $184.48 and its 200-day simple moving average is $150.83.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the firm earned $1.19 EPS. The business's revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on ILMN shares. Barclays lifted their price objective on Illumina from $145.00 to $160.00 and gave the stock an "underweight" rating in a research report on Friday, July 31st. Zacks Research raised Illumina from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 3rd. Royal Bank Of Canada lifted their price target on Illumina from $170.00 to $230.00 and gave the stock an "outperform" rating in a report on Friday, July 31st. Piper Sandler reissued an "overweight" rating and set a $225.00 price target (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Finally, Guggenheim upped their price objective on shares of Illumina from $200.00 to $226.00 and gave the company a "buy" rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $188.40.

Insider Buying and Selling

In other Illumina news, insider Scott M. Davies sold 615 shares of the stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the sale, the insider owned 20,338 shares of the company's stock, valued at $4,067,600. This trade represents a 2.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 283,269 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $199.61, for a total transaction of $56,543,325.09. Following the completion of the sale, the director directly owned 2,089,425 shares in the company, valued at approximately $417,070,124.25. This trade represents a 11.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,415,351 shares of company stock valued at $255,966,311 in the last three months. 2.90% of the stock is currently owned by insiders.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source